Generate Biomedicines, Inc. (GENB): who owns it and who trades it
As of Nov 16, 2026, GENB insiders reported 2 open-market sales worth $201K and 6 purchases worth $25.3M in the last 12 months, with 92% of the sale value made under pre-set 10b5-1 plans. The largest seller was Frances Arnold (Director), with $201K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Generate Biomedicines
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns GENB
86 funds and institutions reported GENB shares worth $1.7B at the end of Q2 2026, about 78% of the company. The largest holder is Flagship Pioneering, LLC with 48.9%.
Funds and institutions (13F) 78%Everyone else 22%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Flagship Pioneering, LLC | 62.67M | 48.89% | $1.1B | No change |
| FMR LLC (Fidelity) | 5.22M | 4.07% | $88.1M | +24% |
| Capital World Investors | 4.22M | 3.29% | $71.1M | +5% |
| Braidwell LP | 3.28M | 2.56% | $55.4M | -9% |
| T. Rowe Price Associates | 2.16M | 1.68% | $36.4M | +2% |
| Norges Bank | 2.09M | 1.63% | $35.3M | New |
| ARCH Venture Management, LLC | 1.94M | 1.52% | $32.8M | No change |
| HarbourVest Partners LLC | 1.72M | 1.34% | $29.1M | No change |
| BlackRock, Inc. | 1.66M | 1.29% | $28M | New |
| Baker Bros. Advisors LP | 1.42M | 1.11% | $24M | No change |
| JPMorgan Chase & Co | 1.41M | 1.10% | $23.8M | New |
| Deep Track Capital, LP | 1.33M | 1.04% | $22.5M | New |
| ARK Investment Management LLC | 1.28M | 1.00% | $21.7M | +158% |
| Vanguard Capital Management LLC | 1.13M | 0.88% | $19.1M | +763% |
| Harvard Management Co Inc | 1.11M | 0.87% | $18.7M | No change |
| Nvidia Corp | 833,325 | 0.65% | $14.1M | No change |
| Davern Capital Partners, LP | 824,679 | 0.64% | $13.9M | +39% |
| Siren, L.L.C. | 736,104 | 0.57% | $12.4M | No change |
| Geode Capital Management, LLC | 735,003 | 0.57% | $12.4M | +522% |
| State Street Corp | 526,565 | 0.41% | $8.9M | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, GENB insiders reported $25.3M of open-market purchases and $201K of sales. 92% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Frances Arnold | Director | Sale plan | 11,409 | $16.19 | $185K | Form 4 |
| Sep 1, 2026 | Frances Arnold | Director | Sale | 1,000 | $16.00 | $16K | Form 4 |
| Mar 4, 2026 | Michael Nally | CEO | Purchase | 20,000 | $12.00 | $240K | Form 4 |
| Mar 2, 2026 | Beth Grous | Chief People Officer | Purchase | 300 | $16.00 | $4.8K | Form 4 |
| Mar 2, 2026 | Jason Silvers | CFO | Purchase | 1,000 | $16.00 | $16K | Form 4 |
| Mar 2, 2026 | Jason Silvers | CFO | Purchase | 500 | $16.00 | $8K | Form 4 |
| Mar 2, 2026 | Nutritional Health LTP Fund General Partner LLC +7 | 10% owner | Purchase | 1.56M | $16.00 | $25M | Form 4 |
| Mar 2, 2026 | Jane L Mendillo | Director | Purchase | 1,500 | $16.00 | $24K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Nutritional Health LTP Fund General Partner LLC | 10% owner | $25M | – | Mar 2, 2026 |
| Michael Nally | Chief Executive Officer, Director | $240K | – | Mar 4, 2026 |
| Frances Arnold | Director | – | $201K | Oct 29, 2026 |
| Jason Silvers | President & CFO | $24K | – | Mar 2, 2026 |
| Jane L Mendillo | Director | $24K | – | Mar 2, 2026 |
| Beth Grous | Chief People Officer | $4.8K | – | Mar 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GENB short interest
Moderate short interest. 7.0% of GENB shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 163%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.08M GENB shares were sold short, 7.0% of the shares outstanding, up 1.7% from the report before. At the average daily volume of 1.02M shares, buying them all back would take about 8.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.08M | 7.04% | +2% | 1.02M | 8.9 |
| Oct 15, 2026 | 8.93M | 6.96% | +20% | 1.12M | 8.0 |
| Sep 30, 2026 | 7.42M | 5.78% | +3% | 1.29M | 5.8 |
| Sep 15, 2026 | 7.18M | 5.59% | -4% | 991,064 | 7.2 |
| Aug 31, 2026 | 7.46M | 5.81% | +2% | 1.99M | 3.7 |
| Aug 14, 2026 | 7.29M | 5.68% | +0% | 482,706 | 15.1 |
| Jul 31, 2026 | 7.28M | 5.67% | +4% | 477,224 | 15.2 |
| Jul 15, 2026 | 6.99M | 5.45% | +18% | 744,702 | 9.4 |
| Jun 30, 2026 | 5.92M | 4.62% | +30% | 1.47M | 4.0 |
| Jun 15, 2026 | 4.55M | 3.55% | +11% | 939,384 | 4.8 |
| May 29, 2026 | 4.09M | 3.19% | +18% | 843,880 | 4.8 |
| May 15, 2026 | 3.45M | 2.69% | +9% | 404,364 | 8.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Generate Biomedicines company events
Generate Biomedicines filed 5 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 12, 2026.
- Nov 12, 2026ResultsReleased financial results. Filing
- Aug 26, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 2, 2026RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold GENB
4 of the 50 well-known investors we track reported holding GENB in their latest 13F filing. The largest position is Cathie Wood's, worth $29.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 1.96M | $29.5M | 0.2% | +53% |
| Israel Englander · Millennium Management | Q3 2026 | 541,886 | $8.1M | 0.0% | +2371% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 38,272 | $575K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 29,603 | $445K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named GENB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G | 5.6% |
| Nov 5, 2026 | FMR LLC | 13G | 5.6% |
Questions about Generate Biomedicines, Inc. (GENB) stock
Who owns the most GENB stock?
The largest reported owner of Generate Biomedicines, Inc. (GENB) is Flagship Pioneering, LLC, with 48.9% of the company. In total, 86 funds and institutions reported holding GENB at the end of Q2 2026, together about 78% of the shares. See the largest owners.
Are GENB insiders buying or selling?
In the last 12 months, GENB insiders reported 6 open-market purchases worth $25.3M and 2 sales worth $201K. The latest trade was on Oct 29, 2026. See every trade.
What is the short interest in GENB?
As of Oct 30, 2026, 9.08M GENB shares were sold short, 7.0% of the shares outstanding, up 1.7% from the report before. At the average daily volume of 1.02M shares, buying them all back would take about 8.9 trading days (days to cover). See the history.
Which famous investors hold GENB?
4 of the 50 well-known investors we track reported GENB in their latest 13F filing, including Cathie Wood, Israel Englander, Ken Griffin. The largest position is worth $29.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.